Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Florent MarguetFlorent MarguetCristina AlexandruOlivier LangloisOvidiu VeresezanVianney GilardMarion DavidAnnie LaquerriereChantal HanzenIsabelle TennevetFrédéric Di FioreFlorian ClatotPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018)
Platelet decrease at W6 ≥ 35% during the RT-TMZ phase is an early and simple predictive marker of clinically relevant TMZ-induced thrombocytopenia during TMZ maintenance.